Osiris Therapeutics reported that its Grafix wound-care product, which releases stem cells straight to the wound site to allow tissue regeneration, demonstrated effectiveness in treating patients with diabetic foot ulcers in a postmarket study. The study found that complete wound closure was achieved in 62% of patients who were treated with Grafix, compared with 21% of those who received traditional therapy.
Wound-care product from Osiris shows positive trial results
SmartBrief Job Listings for Health Care
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||